M

Mitsubishi Chemical Group Corp
F:M3C0

Watchlist Manager
Mitsubishi Chemical Group Corp
F:M3C0
Watchlist
Price: 25.8 EUR 1.57% Market Closed
Market Cap: €7.3B

Mitsubishi Chemical Group Corp
Investor Relations

Mitsubishi Chemical Group Corporation, a cornerstone of Japan’s industrial landscape, intricately weaves its operations across a spectrum of chemical and material science sectors. As the flagship of Mitsubishi’s chemical subsidiaries, it has crafted a robust portfolio that underscores its dedication to innovation and sustainability. The company’s reach extends globally, leveraging research and development to pioneer advanced solutions in fields like performance products, industrial materials, and health care. By strategically aligning its resources to address the ever-evolving demands of these dynamic industries, Mitsubishi Chemical has positioned itself as a key player at the intersection of tradition and innovation.

The powerhouse generates revenue through a diversified approach, integrating its activities from core chemicals to customized solutions tailored for clients across various sectors. Mitsubishi’s business spans the production of petrochemicals and carbon products, leading to advanced polymers and functional materials for electronics and automotive industries, showcasing its ability to adapt and thrive in a competitive marketplace. Additionally, its ventures into healthcare and life sciences reflect an acute awareness of global trends and the needs of an aging population, indicating a commitment to long-term sustainable growth. By capturing the synergy of its operations, Mitsubishi Chemical not only delivers essential materials but also positions itself as a provider of solutions, ensuring its continued relevance and economic success.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Oct 31, 2025
AI Summary
Q2 2026

Revenue Decline: Sales revenue for the first half was JPY 1,799.1 billion, down 10% year-on-year, reflecting weak markets in MMA, Basic Materials, and Polymers.

Profit Mix: Net income surged 169% YoY to JPY 110.1 billion, boosted by the sale of Mitsubishi Tanabe Pharma, despite core operating income dropping 12% YoY.

Guidance Lowered: Full-year core operating income guidance was cut to JPY 250 billion (down 6%), and net income guidance reduced to JPY 125 billion, citing weak markets and restructuring costs.

Segment Divergence: Specialty Materials outperformed with a 37% rise in core operating income, while MMA & Derivatives profits plunged 84% YoY due to market oversupply and weak prices.

Dividends Maintained: The annual dividend forecast is held at JPY 32 per share, unchanged from prior guidance.

Restructuring & Cost Cuts: Structural reforms and asset optimization drove cost reductions, with special retirement expenses and workforce reductions underway.

Robotaxi Opportunity: Strong profit improvement forecast in Advanced Composites & Shapes, driven by robotaxi applications and cost rationalization.

Key Financials
Sales Revenue
JPY 1,799.1 billion
Core Operating Income
JPY 126.1 billion
Net Income Attributable to Owners of Parent
JPY 110.1 billion
Dividend per Share
JPY 32
Free Cash Flow
JPY 335.6 billion
Net Debt-to-Equity Ratio
0.83
Other Earnings Calls

Management

Mr. Ken Fujiwara
Executive VP, General Counsel & Director
No Bio Available
Frank Randall Queen
Executive VP & Head of Specialty Materials
No Bio Available
Mr. Manabu Chikumoto
President, CEO, Representative Corporate Executive Officer & Director
No Bio Available
Mr. Minoru Kida
VP & CFO
No Bio Available
Toshiya Katsuragi
Senior VP & CTO
No Bio Available
Isao Yano
Senior VP & Chief Compliance Officer
No Bio Available
Mr. Osamu Shimizu
General Manager of Corporate Communications Office
No Bio Available
Masahiko Tanaka
VP & Chief Human Resource Officer
No Bio Available
Mr. Yuji Ichimura
Senior VP & Chief Digital Officer
No Bio Available
Mr. Akihiro Tsujimura M.B.A.
Executive VP & Head of Pharma
No Bio Available

Contacts

Address
TOKYO-TO
Chiyoda-ku
Palace Bldg., 1-1-1, Marunouchi
Contacts
+81367487200
www.mcgc.com